Articles

Brain metastases: Systemic treatment approach in 2017

BJMO - volume 12, issue 3, may 2018

S. Demartin , L. Duck MD, L. Carestia , T. Connerotte MD, PhD, R. Poncin MD, N. Whenham MD

This review proposes to go through reasonable systemic therapy options in brain metastases, notably immune checkpoint inhibitors and oncogen-driven targeted therapies. We deliberately focus on drugs currently available in Belgium in clinical practice. In the large majority of cases, clinical trials – in particular registration trials – exclude patients with brain metastases. Therefore we have to deal with small size non-randomised phase II trials or retrospective analysis with the known caveats of highly selected patients and numerous biases.

(BELG J MED ONCOL 2018:12(3):96–102)

Read more
X